Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico

María Verónica Cuevas-González¹, Celia Minerva Díaz-Aguirre¹, Enrique Echevarría-y-Pérez¹, Juan Carlos Cuevas-González²

¹Department of Maxillofacial Prosthetics, General Hospital of México, Mexico City, ²Department of Stomatology, Institute of Biomedical Sciences, Autonomous University of Ciudad Juárez, Ciudad Juárez, Mexico

Abstract (J Korean Assoc Oral Maxillofac Surg 2016;42:365-369)

Objectives: To determine the prevalence and oral characteristics of cancer patients treated with bisphosphonates in the oncology and maxillofacial prosthesis departments of the General Hospital of Mexico between 2011 and 2013.

Materials and Methods: This cross-sectional study included patients who received prior treatment with bisphosphonates; an intraoral examination was performed by 2 standardized examiners.

Results: The prevalence of bisphosphonate-related necrosis in 75 patients was 2.6%; the most common malignancy was breast cancer (84.0%), followed by prostate cancer (16.0%). Exostosis was present in 9.3% of patients and the mean Decayed, Missing, Filled Teeth index was 4.64; 44.0% of the study group had a Community Periodontal Index value between 2 and 2.9 (mean, 0.60).

Conclusion: A detailed intraoral assessment must be performed before initiating treatment with bisphosphonates to identify risk factors for osteonecrosis.

Key words: Prevalence, Osteonecrosis, Bisphosphonates

[paper submitted 2016. 1. 17 / revised 2016. 3. 29 / accepted 2016. 4. 16]
incidence in patients with malignant neoplasm who took zoledronic acid was 0.019-1.9 per 10,000 patients. There are no data on the prevalence of ONJ in Mexico.

In the present study, we determined the prevalence and oral characteristics of cancer patients treated with bisphosphonates in the oncology and maxillofacial prosthesis departments of the General Hospital of Mexico between 2011 and 2013. We hypothesized that patients with bisphosphonate treatment would not need invasive dental treatment.

II. Materials and Methods

We reviewed the clinical records of patients from the medical oncology and maxillofacial prosthesis departments of the General Hospital 'Dr. Eduardo Liceaga', in Mexico City. Patients treated with bisphosphonates during their scheduled appointments from January 2011 to December 2013 were recruited for this study. Only the patients who signed an informed consent form were included in the study. This study was approved by the Institutional Review Board of General Hospital of México (IRB no. 4870).

All participants received intraoral scans performed by 2 examiners and cases with ONJ were identified. The intraoral examinations were based on the Decayed, Missing, Filled Teeth (DMFT) index and Community Periodontal Index (CPI). Mucous membranes and other parts of the oral cavity were also examined to identify exostosis, which is considered a risk factor for ONJ.

All data, including clinical records, type of bisphosphonate used, number of cycles applied, route of administration, neoplastic disease, concomitant use of corticosteroids and frequency of diabetes or hypertension, were evaluated. Descriptive statistics and \( \chi^2 \) test were used to identify associations. A \( P \)-value less than 0.05 was considered statistically significant. The database and statistical analysis were performed using IBM SPSS Statistics 20 (IBM Co., Armonk, NY, USA).

III. Results

Overall, 84.0% of the study population were females and the average age was 55.91 years with a \( \sigma \) value of 13.79. The subjects were subdivided into four groups based on age: 34 years and under, 35 to 49 years, 50 to 74 years, and 75 years and older; 40 patients (53.3%) were in the 50 to 74 years group.

The most common neoplasia treated by bisphosphonates was breast cancer (84.0%) followed by prostate cancer (16.0%). In 100% of cases, the bisphosphonate was zoledronic acid at doses of 3 mg in 3 patients (4.0%) and 4 mg in 72 patients (96.0%). Additionally, 32.0% of the population was taking corticosteroids.

Of 75 patients, 2.6% had ONJ. One 41-year-old male was diagnosed with prostate cancer and one 42-year-old female with breast cancer. Both subjects received a monthly dose of 4 mg zoledronic acid for 11 and 26 cycles, respectively; neither patient had diabetes or hypertension.

Regarding chronic diseases, hypertension was diagnosed in 32% of the study population vs. 13.3% with type 2 diabetes. The minimum number of cycles was 1 in 6 patients (8.0%) and the maximum was 30 cycles in 1 patient (1.3%), resulting in an average of 9.35 cycles. (Table 1)

Exostosis was observed in 9.3% of subjects. The mean DMFT index was 4.64 and 44.0% of the study population had a CPI between 2 and 2.9 (mean 0.60 overall). Statistical analysis showed a correlation between age and the number of cycles (\( \chi^2=30.187; P=0.001 \)).

In patients with ONJ, the lesions were located bilaterally in the jaw (Fig. 1) with an area of exposed bone 0.5 to 1 cm in length. The soft tissue did not show any signs or symptoms
Osteonecrosis and oral characteristics of oncologic patients treated with bisphosphonates

In 2014, the AAOMS estimated the risk of developing ONJ in patients treated with zoledronic acid was between 50 and 100 times higher than in patients treated with placebo. Although zoledronic acid is the most commonly used drug to prevent bone damage, denosumab has become important due to its advantages compared to bisphosphonate. Mainly, denosumab is not fixed to the bone; however, the risk of developing ONJ in these patients is the same as those treated with zoledronic acid. In our study, 100% of cases were treated with zoledronic acid since it is the drug mainly reported in the literature.

In 2015, Kos reported the incidence and the risk factors associated with the development of ONJ. Advanced age is a risk factor since aging impairs healing and regeneration processes and increases dental problems such as tooth decay and periodontal disease. In our study, the average patient age was 55.91 years. We found a correlation between age and the number of cycles of bisphosphonates. Older patients were exposed to bisphosphonates for longer periods. The approximate age at the disease onset was 40 years whereas the average age of the cohort was 55 years.

Breast cancer is predominant among females. In Mexico, this neoplasm has had the highest prevalence since 2011, accounting for 11.34% of all cancer cases. A study by Robles-Castillo et al. in 2011 reported the mean age of breast cancer patients was 53.64 years, which is similar to our study population (55.91 years).

Bonacina et al. reported that less than 50% of patients had breast cancer, followed by prostate (18.8%), lung and liver cancer. Similar to our study group, patients received zoledronic acid at a dose of 4 mg with an average therapy duration of 8 months.

The main risk factor for ONJ is the exposure time to bisphosphonate. In 2007, Marx found that bisphosphonates accumulate in bone and when administered intravenously,
often accumulate faster due to the higher dose. Thus, dental treatments where bone is exposed are limited after the third application.

The population in this study underwent 9.35 treatment cycles on average; thus, clinicians should ensure that treatments do not compromise bone integrity, underscoring the importance of performing a comprehensive assessment before initiating treatment and taking into account the effects on bone for the 10-year period after the last application.\(^\text{17}\)

The risk factors for developing ONJ can be systemic or local. Diabetes is a systemic factor because it is associated with bone microvascular ischemia, endothelial cell dysfunction and decreased bone remodeling. Overall, 32% of patients in our cancer center had diabetes mellitus type 2, thus, we encouraged the use of preventive protocols in this subgroup.\(^\text{18}\)

In 2009, Ruggiero et al.\(^\text{19}\) concluded that patients with exostosis have a thin mucosa and are susceptible to lacerations due to food or poor-fitting dentures, which can cause direct damage to the bone. Fuentes et al.\(^\text{20}\) reported an exostosis prevalence of 5.6% while in our study, the prevalence was 13.3%. Exostosis should be considered when implementing medical-dental care protocols to educate patients regarding the irritating effects of buccal exostosis due to hard foods and prosthetic attachments.

Periodontal disease is a local risk factor that has become increasingly important due to its relationship with ONJ. The AAOMS has reported that individuals with periodontal disease have a 7-fold greater risk of developing ONJ.\(^\text{7}\) The CPI measures the need of periodontal treatment, ranging from 0 (no need) to 4 or higher (needs periodontal surgery). Overall, 44.0% of the study population had CPI values ranging from 2 to 2.9 and only 8.0% of the population did not require scaling and root planing treatment, thus, improving oral hygiene is necessary.

Although tooth decay lesions are not directly associated with the development of ONJ, patients must be educated regarding oral health and made aware of the consequences when caries progresses and becomes a trigger for ONJ.

The mean DMFT in the General Hospital of Mexico was 4.64, indicating the population has 4.64 teeth with some past or present caries, similar to what was reported by de la Fuente-Hernández et al.\(^\text{21}\) (index of 5) in different populations.

In 2011, Bonacina et al.\(^\text{22}\) analyzed 282 patients and concluded that preventive therapies are essential to halt the development of ONJ. As discussed, including control patients that do not undergo treatment with bisphosphonates, significantly decreases the incidence of ONJ. The care provided by professional health specialists in dentistry is crucial to prevent this disease.

V. Conclusion

According to our study results, females with an average age of 55.91 years were more exposed to bisphosphonate (zoledronic acid), and 53% (CPI=2 to 3 or more) required dental treatment that involved bone manipulation. Thus, we propose the following recommendations:

1. Identify the population at risk in a timely manner. Based on our study results, this population was females over 50 years of age treated with bisphosphonates and who had a periodontal disease. The goal is to control the local risk factors for the development of ONJ.

2. Dental and medical staff should be aware of the importance of performing an adequate intraoral assessment to identify local risk factors before initiating treatment with bisphosphonates. A follow-up throughout the treatment period is important to maintain the health of the oral cavity and prevent the occurrence of ONJ.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

ORCID

María Verónica Cuevas-González, http://orcid.org/0000-0003-3112-4893

Celia Minerva Díaz-Aguirre, http://orcid.org/0000-0002-5147-9133

Enrique Echevarría-y-Pérez, http://orcid.org/0000-0002-1250-2564

Juan Carlos Cuevas-González, http://orcid.org/0000-0002-6981-8025

References

1. Hellstein JW, Marek CL. Bisphosphonate osteoclonemocrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.

2. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.

3. Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Ha-
nover Park: Quintessence Publishing; 2007:1-65.

4. Correia Vde F, Caldeira CL, Marques MM. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dent Traumatol 2006;22:312-7.

5. Filleul O, Crompton E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24.

6. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-65.

7. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.

8. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 2013;24:237-44.

9. Casal C, Someso E, Álvarez AM, Fariña J, Álvarez T. Osteonecrosis de maxilares relacionada con el uso de bifosfonatos [Osteonecrosis of the jaws related with the use of bisphosphonates]. Farmacéuticos de Atención Primaria 2012;10:9-14.

10. Varun B, Sivakumar T, Nair BJ, Joseph AP. Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: a systematic review. J Oral Maxillofac Pathol 2012;16:210-4.

11. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13.

12. Chang JT, Hazboun RC, Chang TI. Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:2381.

13. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci 2015;11:319-24.

14. Arce C, Bargalló E, Villaseñor Y, Gamboa C, Lara F, Pérez V, et al. Oncoguía: Cáncer de Mama. Mexico City: Instituto Nacional de Cancerología; 2011:77-86.

15. Robles-Castillo J, Ruvalcaba-Limón E, Maffuz A, Rodriguez-Cuevas S. Breast cancer in Mexican women under 40. Ginecol Obstet Mex 2011;79:482-8.

16. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011;77:b147.

17. Junquera LM, Martin-Granizo R. Diagnóstico, prevención y tratamiento de la osteonecrosis de los maxilares por bisfosfonatos. Recomendaciones de la Sociedad Española de Cirugía Oral y Maxilofacial (SECOM). Rev Esp Cir Oral y Maxilofac 2008;30:145-56.

18. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5.

19. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrtra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.

20. Fuentes R, Borie E, Sanhueza Campos A, Rebolledo Soto K, Parra Villega P. Presencia de exostosis orales en pacientes de la ciudad de Temuco, Chile. Avances Odontostomatol 2012;28:63-9.

21. de la Fuente-Hernández J, González de Cossío M, Ortega-Maldonado M, Sifuentes-Valenzuela MC. Caries y pérdida dental en estudiantes preuniversitarios mexicanos [Dental decay and tooth loss at the high school level in Mexican students]. Salud Pública Méx 2008;50:235-40.